[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
7-Feb-2008

[ | E-mail ] Share Share

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
@jclinicalinvest

VEGF-B helps nerve cells cheat death without unwanted side effects

The prototypical member of the VEGF family of proteins, VEGF, has recently been shown to protect cells in the nervous system from death and degeneration. However, its clinical utility in this regard is limited, because it also induces blood vessel growth, a process known as angiogenesis. In a new study, Xuri Li and colleagues at the National Institutes of Health, Bethesda, have revealed that the VEGF family member VEGF-B acts as a potent inhibitor of murine retinal cell death while exerting minimal angiogenic effects.

In addition to inhibiting expression of cell-death-related genes, VEGF-B was shown to reduce the death of murine retinal cells in culture models of cellular injury and in mouse models of ocular neurodegenerative disorders. Furthermore, VEGF-B treatment inhibited brain cell death in a mouse model of stroke. As the concentration of VEGF-B required for retinal protection did not lead to angiogenesis in the mouse retina, the authors concluded that VEGF-B might provide a new therapeutic option for the treatment of neurodegenerative disease.

###

TITLE: VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats

AUTHOR CONTACT:
Xuri Li
National Institutes of Health, Bethesda, Maryland, USA.
Phone: (301) 496-4103; Fax: (301) 480-2640; E-mail: lixur@nei.nih.gov.

View the PDF of this article at: https://www.the-jci.org/article.php?id=33673



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.